We are live on
!
Find out more
AC
Axon Capital Portfolio holdings
AUM
$69.3M
This Fund
S&P 500
This Quarter
Est. Return
+9.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$47.6M
AUM Growth
+$4.36M
(+10%)
Cap. Flow
+$727K
Cap. Flow
% of AUM
1.53%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
1
Reduced
–
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$5.57M |
| 2 |
Centene
CNC
|
+$2.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.75M |
| 2 |
McKesson
MCK
|
+$2.67M |
| 3 |
Equifax
EFX
|
+$2.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 47.39% |
| 2 | Healthcare | 30.65% |
| 3 | Consumer Discretionary | 14.85% |
| 4 | Financials | 7.11% |
| 5 | Industrials | 0% |
Similar funds
YEPX
WG
FWA
VIM
CCM
FCI
SCH
BWM
Axon Capital's Q1 2019 Portfolio in Review
As of Q1 2019, Axon Capital held 10 positions worth $47.6M, up 10% from $43.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Axon Capital's Q1 2019 filing shows 1 new, 1 increased and 3 closed positions. Its largest new stake was PTC Therapeutics: 165,800 shares worth $6.24M. The largest sale was Allergan plc, an estimated $2.75M.
By sector, the portfolio is most concentrated in Communication Services at 47% of assets, up from 45% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Axon Capital's largest Q1 2019 buy was PTC Therapeutics: 165,800 shares worth $6.24M.
- Axon Capital added most to Centene in Q1 2019, an estimated $2.82M increase.
- Axon Capital fully exited Allergan plc in Q1 2019, selling an estimated $2.75M.
- Axon Capital's ten largest holdings make up 100% of its $47.6M portfolio in Q1 2019.
- Axon Capital opened 1 new position and closed 3 in Q1 2019.
- Axon Capital's portfolio value rose 10% quarter-over-quarter to $47.6M.
Based on Axon Capital's 13F filing for Q1 2019, filed 15 May 2019.